← All trials
NCT06119789
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Nov 30, 2027
- Completion date
- Aug 31, 2033
- First posted
- Nov 7, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 96
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OsloLead sponsor
- University of BergenCollaborator
- Helse FonnaCollaborator
- Helse FordeCollaborator
- Northern Norway Regional Health AuthorityCollaborator
- University of StavangerCollaborator
- Helse Møre og Romsdal HFCollaborator
- Nordland HospitalCollaborator
- University of OsloOverall official - principal investigator
- University of OsloReponsible party - principal investigator
- Sorlandet Hospital HFCollaborator
- Sykehuset Innlandet HFCollaborator
- Sykehuset OstfoldCollaborator
- The Hospital of VestfoldCollaborator
- University Hospital of North NorwayCollaborator
- University of OsloSponsor investigator
- University of OsloOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.